[go: up one dir, main page]

Avendaño et al., 1970 - Google Patents

A clinical study with continuous low doses of megestrol acetate for fertility control: Oil solution versus tablet formulation

Avendaño et al., 1970

Document ID
5921777538645264270
Author
Avendaño S
Tatum H
Rudel H
Avendaño O
Publication year
Publication venue
American Journal of Obstetrics and Gynecology

External Links

Snippet

Dose response, contraceptive efficacy, and menstrual cycle control were tested in 667 normal fertile women using daily oral administration of megestrol acetate (MA) in either an oil solution or a tablet form. The occurrence of a regular menstrual bleeding pattern suggests …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00—Drug, bio-affecting and body treating compositions
    • Y10S514/841—Contraceptive
    • Y10S514/843—Female mammal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00—Drug, bio-affecting and body treating compositions
    • Y10S514/899—Menstrual disorder

Similar Documents

Publication Publication Date Title
Diaz et al. A five-year clinical trial of levonorgestrel silastic implants (Norplant™)
Yuzpe et al. Ethinylestradiol and dl-norgestrel as a postcoital contraceptive
AU635270B2 (en) Treatment of postmenopausal disorders
Wilson et al. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen
Adlercrutz et al. Oral contraceptives and liver damage
US3836651A (en) Novel oral contraceptive combination
Shaaban et al. A prospective study of NORPLANT® implants and the Tcu 380Ag IUD in Assiut, Egypt
Coutinho et al. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant
Mora et al. Clinical evaluation of an oral progestin contraceptive, R-2323, 5mg, administered at weekly intervals
Avendaño et al. A clinical study with continuous low doses of megestrol acetate for fertility control: Oil solution versus tablet formulation
Serup et al. EFFECTIVITY AND ACCEPTABILITY OF ORAL CONTRACEPTIVES CONTAINING NATURAL AND ARTIFICIAL ESTROGENS IN COMBINATION WITH A GESTAGEN: A controlled double‐blind investigation
Bounds et al. A randomized double‐blind trial of two low dose combined oral contraceptives
Bagshaw et al. Ethinyl oestradiol and D‐norgestrel is an effective emergency postcoital contraceptive: a report of its use in 1,200 patients in a family planning clinic
JPS60100520A (en) Hormonal treatment for disturbance of periodic menopause, menopause and post-menopause, composition and composite medicine wrapped product
Elstein et al. The effect of daily norethisterone (0.35 mg) on cervical mucus and on urinary LH, pregnanediol and oestrogen levels
Johnson Contraception--the morning after
Wallach et al. Contraceptive use and subsequent fertility
Rice-Wray et al. The acceptability of oral progestins in fertility control
Buttermore et al. Six years of clinical experience using postcoital contraception in college women
Rice-Wray et al. Clinical study of a continuous daily micro-dose progestogen contraceptive—d-norgestrel
Glasier Combined hormonal contraception
Mishell Jr et al. Life table analysis of a clinical study of a once-a-month oral steroid contraceptive: Quinestrol—Quingestanol
Swenson et al. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh
US3660574A (en) Method of controlling fertility employing quingestanol acetate
PINKERTON et al. Post‐Pill infertility